Alterity Therapeutics ADR Logo
US02155X1063

Alterity Therapeutics ADR

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Kaufen
  5
Halten
  3
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie6 / 18
Levermann-Strategie-5 / 13
Powered byaktien.guide

News


  • Alterity Therapeutics to Provide Corporate Update in Fireside Chat

    MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will provide a corporate update with a focus on the progress made on the ATH434 development program in Multiple System Atrophy since the Company released positive Phase 2 data in January.» Mehr auf globenewswire.com


  • Alterity Therapeutics Prominently Featured at the International MSA Congress

    – ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.» Mehr auf globenewswire.com


  • Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

    MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MSA Congress taking place May 9 - 11, 2025 in Boston, MA, USA. The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Alterity Therapeutics ADR einen Umsatz von +479,82k und ein Nettoeinkommen von 2,14 Mio
(EUR)Dez. 2024
YOY
Umsatz+479,82k-
Bruttoeinkommen+460,82k-
Nettoeinkommen2,14 Mio-
EBITDA2,25 Mio-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+52,15 Mio
Anzahl Aktien
14,80 Mio
52 Wochen-Hoch/Tief
+4,98 - +0,85
DividendenNein
Beta
0,72
KGV (PE Ratio)
2,59
KGWV (PEG Ratio)
0,10
KBV (PB Ratio)
+6,58
KUV (PS Ratio)
+24,51

Unternehmensprofil

Alterity Therapeutics Limited beschäftigt sich mit der Erforschung und Entwicklung von therapeutischen Medikamenten zur Behandlung der Alzheimer-Krankheit, der Huntington-Krankheit, der Parkinson-Krankheit und anderer neurologischer Erkrankungen in Australien. Der führende Medikamentenkandidat des Unternehmens ist ATH434, der die klinische Phase I zur Behandlung der Parkinson-Krankheit abgeschlossen hat. Darüber hinaus entwickelt es PBT2, das eine klinische Studie der Phase IIa zur Behandlung der Alzheimer-Krankheit abgeschlossen hat. Das Unternehmen war früher als Prana Biotechnology Limited bekannt und änderte im April 2019 seinen Namen in Alterity Therapeutics Limited. Alterity Therapeutics Limited wurde 1997 gegründet und hat seinen Hauptsitz in Melbourne, Australien.

Name
Alterity Therapeutics ADR
CEO
David A. Stamler
SitzMelbourne, vic
Australien
Website
Industrie
Chemikalien
Börsengang
Mitarbeiter10

Ticker Symbole

BörseSymbol
NASDAQ
ATHE
Frankfurt
PBNN.F
München
PBNN.MU
🍪

Parqet nutzt Cookies.Erfahre Mehr